MIMEDX GROUP, INC. Q3 FY2025 earnings call

Chief Executive Officer Joe Capper highlighted that third quarter performance was outstanding with record quarterly revenue, adjusted EBITDA, and adjusted EBITDA margin. The team's focus drove superior results. Strategic priorities include continuing to innovate and diversify the product portfolio, with products like EPIEFFECT, EPIXPRESS, CELERA, and EMERGE being advanced. Progress in the surgical market was noted with 26% growth in the third quarter, and initiatives such as the co-marketing pilot with Vaporox were ongoing. Customer intimacy initiatives via MiMedx Connect were also emphasized. Discussion of Medicare reimbursement reforms, including the Wiser model, proposed physician fee schedule, and LCDs, and the company's readiness for any scenario was part of the management statement.

Third quarter net sales reached $114 million, representing a 35% year-over-year growth. The Wound franchise contributed $77 million in sales, a 40% year-over-year increase, accounting for approximately 67.5% of net sales. The Surgical franchise generated $37 million in sales, a 26% year-over-year increase, making up around 32.5% of net sales. GAAP gross profit for the third quarter was approximately $95 million, a 38% increase from the prior year. Non-GAAP adjusted gross margin was 88% in the quarter, and the full-year non-GAAP gross margin is expected to be around 85%.

Full year 2025 revenue growth guidance has been increased from the low teens to the mid- to high teens. The full year adjusted EBITDA margin is expected to be at least in the mid-20s as a percentage of net sales. For 2026, due to uncertainty regarding CMS final rules, no base case projection from proposed numbers is being made currently, but the company believes it is well-positioned to gain market share post-reimbursement reform.

Risks include competition, access to customers, the reimbursement environment, unforeseen circumstances and delays. These risks are also detailed in the Risk Factors section of the annual report on Form 10-K and quarterly report on Form 10-Q.

Q: Frank Takkinen asked about Q4 guidance and preparation for post-January 1 reforms.

A: Doug Rice noted Q4 comps will be tougher than Q3 but momentum in surgical and wound businesses will continue. Joe Capper added Q4 back of December may be more difficult to predict but the company has great momentum.

Q: Chase Knickerbocker inquired about feedback on suggestions regarding pass-through mechanism and LCDs.

A: Joseph Capper stated no public feedback to share yet.

Q: Carl Byrnes asked about M&A prospects.

A: Joseph Capper mentioned looking for assets that fit the strategic plan, such as those augmenting the product portfolio in wound care and surgical businesses.

Q: Ross Osborn asked about HELIOGEN adoption and AXIOFILL path.

A: Joseph Capper and Doug Rice discussed HELIOGEN's increasing sequential growth and AXIOFILL's need to resubmit arguments and likely have another hearing.

Q: Anthony Petrone asked about demand pull and final rule scenarios.

A: Joseph Capper said no speculation on scenarios yet but welcomed the reimbursement reform and the company's ability to outperform post-reform.